Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
Merck
AstraZeneca
Harvard Business School

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,828,339

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,828,339 protect, and when does it expire?

Patent 6,828,339 protects AMLODIPINE BESYLATE and is included in one NDA.

This patent has four patent family members in four countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,828,339
Title: Amlodipine salt forms and processes for preparing them
Abstract:Amlodipine besylate forms are described, including amlodipine besylate hydrates and novel amlodipine besylate anhydrates. A method of making various amlodipine besylate forms from an aqueous medium as well as the use of the same as a calcium channel blocker are described.
Inventor(s): Ettema; Gerrit J. B. (Nijmegen, NL), Hoorn; Hans (Nijmegen, NL), Lemmens; Jacobus M. (Nijmegen, NL)
Assignee: Synthon BV (Nijmegen, NL)
Application Number:10/300,003
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,828,339
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 6,828,339

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Synthon Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET, ORALLY DISINTEGRATING;ORAL 022026-001 Sep 27, 2007 DISCN No No   Start Trial   Start Trial Y   Start Trial
Synthon Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET, ORALLY DISINTEGRATING;ORAL 022026-002 Sep 27, 2007 DISCN No No   Start Trial   Start Trial Y   Start Trial
Synthon Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET, ORALLY DISINTEGRATING;ORAL 022026-003 Sep 27, 2007 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,828,339

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037565   Start Trial
Australia 2002343257   Start Trial
European Patent Office 1448197   Start Trial
World Intellectual Property Organization (WIPO) 03043635   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Boehringer Ingelheim
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.